Welcome to Browse Page of Biomarker

This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.

The total number entries retrieved from this search are 178
Please click on Biomarker_ID to view detailed information.
Note: Potential Biomarker with * indicates these signatures are candidate biomarkers extracted from experiments on mice, rat or cell lines and they are not validated on human patients'cohort.
Biomarker IDBiomarkerBiomoleculeSubjectRegulationBiomarker's typeExperimentLevel of significanceSourcePMID
2164Apo-A4ProteinHumanDownregulated in HCC patients DiagnosticHCC v/s other liver disease (cirrhosis/ALD) p < 0.01Plasma21160983
2165APO-A1ProteinHumanUpregulated in HCC patients DiagnosticHCC v/s other liver disease (cirrhosis/ALD) p < 0.01Plasma21160983
2166APO-A1, Apo-A4ProteinHumanAPO-A4 Upregulated and APO-A1 downregulated in HCC patients DiagnosticHCC v/s other liver disease (cirrhosis/ALD) p < 0.01Plasma21160983
2167CORO1CProteinHumanUpregulated in liver cancer tissues of HCCLM9-nude mice with spontaneous pulmonary metastasis and higher coronin-1C expression had more advanced stage in patients PrognosticAgressive or advanced-stage HCC v/s less-aggressive HCC; predict metastatic stage p < 0.05Tissue and Cells 20181269
2179lamin B1ProteinHumanUpregulated in liver cancer patients Diagnostic and PrognosticNormal vs HCC; significantly associated with the increased number of tumor nodules , the size of tumors, and tumor stage p < 0.01Plasma19522540
2200AFP, (with cut off 0.9 of AFP in serum )ProteinHumanNA DiagnosticHCC v/s Non-HCC NASerum and Urine29152526
2201BMK, (with cut off 0.40 BMK in Urine)ProteinHumanNA DiagnosticHCC v/s Non-HCC NASerum and Urine29152526
2202AFP, BMK, (with cut off 1.25 of AFP in serum and 0.25 BMK in urine)ProteinHumanNA DiagnosticHCC v/s Non-HCC NASerum and Urine29152526
2203AFP, BMK, (with cut off 1.20 of AFP in serum and 0.27 BMK in urine)ProteinHumanNA DiagnosticHCC v/s Non-HCC NASerum and Urine29152526
2204AFP, BMK, (with cut off 0.90 of AFP in serum and 0.40 BMK in urine)ProteinHumanNA DiagnosticHCC v/s Non-HCC NASerum and Urine29152526
2205AFP, BMK, (with cut off 1.65 of AFP in serum and 0.40 BMK n urine)ProteinHumanNA DiagnosticHCC v/s Non-HCC NASerum and Urine29152526
2206AFP, BMK, (with cut off 0.9 of AFP in serum and 0.75 BMK in urine)ProteinHumanNA DiagnosticHCC v/s Non-HCC NASerum and Urine29152526
2208SULT1A3/4ProteinHumanUpregulated in HCC PrognosticHCC v/s Normal; associated with metastatsis of patients p < 0.01Tissue29025375
2209ITGA2ProteinHumanUpregulated in HCC DiagnosticHBV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2210BMP4ProteinHumanUpregulated in HCC DiagnosticHBV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2211PLCB1ProteinHumanUpregulated in HCC DiagnosticHBV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2212KDM6BProteinHumanDownregulated in HCC DiagnosticHBV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2213MYCProteinHumanDownregulated in HCC DiagnosticHBV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2214ITGA2ProteinHumanUpregulated in HCC DiagnosticHCV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.01Tissue28947976
2215BMP4ProteinHumanUpregulated in HCC DiagnosticHCV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.01Tissue28947976
2216PLCB1ProteinHumanUpregulated in HCC DiagnosticHCV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.01Tissue28947976
2217KDM6BProteinHumanDownregulated in HCC DiagnosticHCV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.001Tissue28947976
2218MYCProteinHumanDownregulated in HCC DiagnosticHCV-associated HCC v/s healthy/non-tumor/cirrhosis p < 0.0001Tissue28947976
2219AFP, GGT, ALT, ASTProteinMale Sprague-Dawley ratsDownregulated Potential Prognostic *HCC v/s Normal/treated with AEA; associated with progression p < 0.0001Serum28900384
2220AFP, DCPProteinHumanAFP upregulated in HCC DiagnosticNormal vs HCC, Cirrhosis p < 0.001Serum19852963
2221DCP, (> =40 mAU/mL)ProteinHumanDCP upregulated in HCC DiagnosticNormal vs HCC, Cirrhosis p < 0.001Serum19852963
2222DCP, (> =150 mAU/mL)ProteinHumanDCP upregulated in HCC DiagnosticNormal vs HCC, Cirrhosis p < 0.001Serum19852963
2223AFP, (> =20 ng/mL)ProteinHumanAFP and DCP upregulated in HCC DiagnosticNormal vs HCC, Cirrhosis p < 0.001Serum19852963
2224AFP, (> =200 ng/mL)ProteinHumanAFP and DCP upregulated in HCC DiagnosticNormal vs HCC, Cirrhosis p < 0.001Serum19852963
2225AFP, DCP, ( DCP with a cut-off value of 86 mAU/mL and AFP with a cut-off value of 21 ng/mL)ProteinHumanAFP and DCP upregulated in HCC DiagnosticHCC v/s Normal p < 0.001Serum25382443
2226AFP, (cut-off value of 21 ng/mL)ProteinHumanAFP upregulated in HCC DiagnosticHCC v/s Normal p < 0.001Serum25382443
2227DCP, (cut-off value of 86 mAU/mL)ProteinHumanDCP upregulated in HCC DiagnosticHCC v/s Normal p < 0.001Serum25382443
2228AFPProteinHumanAFP upregulated in HCC DiagnosticHCC v/s Non-HCC p < 0.001Serum29163838
2229DCPProteinHumanDCP upregulated in HCC DiagnosticHCC v/s Non-HCC p < 0.001Serum29163838
2230AFP, DCP, (DCP >40 mAU/mL, AFP >20 ng/mL)ProteinHumanAFP and DCP upregulated in HCC DiagnosticHCC v/s Non-HCC p < 0.001Serum29163838
2255Enoyl-CoA hydrataseProteinHumanDownregulated in HCC than non-tumor DiagnosticHCC v/s non-tumor p < 0.05Tissue15221772
2256Tropomyosin-beta-chainProteinHumanDownregulated in HCC than non-tumor DiagnosticHCC v/s non-tumor p < 0.01Tissue15221772
2257KetohexokinaseProteinHumanDownregulated in HCC than non-tumor DiagnosticHCC v/s non-tumor p < 0.01Tissue15221772
2258Liver type aldolaseProteinHumanDownregulated in HCC than non-tumor DiagnosticHCC v/s non-tumor p < 0.05Tissue15221772
2259Arginase 1ProteinHumanDownregulated in HCC than non-tumor DiagnosticHCC v/s non-tumor p < 0.01Tissue15221772
2267SPP1RNAs and ProteinHumanUpregulated in PT than PN (with 3 fold change) DiagnosticMetastatic HCC v/s Primary HCC p < 0.01Tissue12640447
2269Phosphoserine aminotransferaseProteinHumanUpregulated in recurrence HCC than non-recurrence HCC (with fold change 3.8) PrognosticEarly recurrence v/s No recurrence HCC p < 0.05Tissue17391314
2270IFP53/Tryptophanyl-Trna synthetaseProteinHumanDownregulated in recurrence HCC than non-recurrence HCC (with fold change 0.27) PrognosticEarly recurrence v/s No recurrence HCC p < 0.05Tissue17391314
2271Peroxiredoxin 3ProteinHumanUpregulated in recurrence HCC than non-recurrence HCC (with fold change 1.82) PrognosticEarly recurrence v/s No recurrence HCC p < 0.05Tissue17391314
2272GRP94 (Tumor rejection antigen 1)ProteinHumanDownregulated in recurrence HCC than non-recurrence HCC (with fold change 0.59) PrognosticEarly recurrence v/s No recurrence HCC p < 0.05Tissue17391314
2273Annexin A1 (Phospholipase A2 inhibitory protein)ProteinHumanDownregulated in recurrence HCC than non-recurrence HCC (with fold change 0.52) PrognosticEarly recurrence v/s No recurrence HCC p < 0.05Tissue17391314
2274Superoxide dismutaseProteinHumanDownregulated in recurrence HCC than non-recurrence HCC (with fold change 0.44) PrognosticEarly recurrence v/s No recurrence HCC p < 0.05Tissue17391314
2275Annexin A2ProteinHumanDownregulated in recurrence HCC than non-recurrence HCC (with fold change 0.42) PrognosticEarly recurrence v/s No recurrence HCC p < 0.05Tissue17391314
2276Annexin A4ProteinHumanUpregulated in recurrence HCC than non-recurrence HCC (with fold change 1.6) PrognosticEarly recurrence v/s No recurrence HCC p < 0.05Tissue17391314
2277L-lactate dehydrogenase B chainProteinHumanUpregulated in recurrence HCC than non-recurrence HCC (with fold change 1.61) PrognosticEarly recurrence v/s No recurrence HCC p < 0.05Tissue17391314

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top